Piper Sandler resumed coverage on Replimune with a new price target

4/17/23 7:34:30 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Piper Sandler resumed coverage of Replimune with a rating of Overweight and set a new price target of $44.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$REPL

Date	Price Target	Rating	Analyst
6/20/2025		Overweight	Cantor Fitzgerald
8/28/2024	$17.00	Buy	ROTH MKM
4/17/2023	$44.00	Overweight	Piper Sandler
11/19/2021	$52.00	Overweight	Piper Sandler
10/15/2021	$60.00	Buy	BTIG Research
8/23/2021	$55.00 → $49.00	Outperform	SVB Leerink
8/9/2021	$56.00 → $55.00	Outperform	SVB Leerink